News

SPI-62, now clofutriben, normalizes cortisol levels in Phase 2 trial

Sparrow Pharmaceuticals’ oral small molecule SPI-62, now being called clofutriben, can lower the levels of free cortisol in the urine of people with Cushing’s syndrome caused by a tumor outside the adrenal glands, including those with Cushing’s disease. Unlike other cortisol-lowering medications, which require careful dosing to prevent…

GRACE trial testing relacorilant in Cushing’s meets primary goal

Among people with endogenous Cushing’s syndrome whose high blood pressure, or hypertension, dropped after five months on relacorilant, that response was maintained when the patients continued treatment for an additional period of three months. That’s according to new data from the randomized withdrawal phase of the Phase 3…

Protocols lacking for reducing risk of VTEs in Cushing’s patients

People with Cushing’s syndrome have an increased risk of venous thromboembolism (VTE), that is, dangerous blood clots that obstruct the normal flow of blood through veins, but most treatment centers don’t have standard procedures for reducing VTE risk in Cushing’s patients, a study indicates. “A specific thromboprophylaxis protocol for patients…

Medication for abdominal pain triggers Cushing’s in woman, 62

The prolonged use of an injectable medication containing an anti-inflammatory corticosteroid to treat abdominal pain led to the onset of Cushing’s syndrome in a 62-year-old woman, as described in a case reported by a team in Florida. The woman was being treated for pain associated with chronic inflammation in the…